Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+3.67%
+1.24%
-5.00%
+24.42%
META
Meta Platforms
$697.71
Chart
$547.27 (+27.49%)
$590.64 (+18.13%)
$676.49 (+3.14%)
$494.78 (+41.01%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+3.67%
+1.24%
-5.00%
+24.42%
META
Meta Platforms
Current Price
$697.71
Login to view Meta Platforms (META) recommendation from the last 90 days from financial news and social media.
Chart
$547.27 (+27.49%)
$590.64 (+18.13%)
$676.49 (+3.14%)
$494.78 (+41.01%)
META Latest Headlines
Meta Platforms Rises 17% Year to Date: Buy Sell or Hold META Stock?. META rides AI-driven ad gains and rising engagement but overvaluation and monetization concerns linger for now.
Today
Pfizer Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial Seeks FDA Approval. ) on Friday announced in a press release the submission of a New Drug Application to the United States Food and Drug Administration (FDA) ).The application covers vepdegestrant for patients with ER-positive (ER)/human epidermal growth factor receptor 2 (HER2)-negative (ER/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with .This submission is based on Phase 3 VERITA
Today
Demystifying Zoom Communications: Insights From 21 Analyst Reviews. Providing a diverse range of perspectives from ish to bearish 21 analysts have published ratings on Zoom Communications (NASDAQ:) in the last three months.The table below offers a condensed view of their recent ratings showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.63111000010418001120011100Analysts have recently evaluated Zoom Communications and provided 12-month price target
Today
Peter Lynch Detailed Fundamental Analysis - META. Below is Valideas guru fundamental report for META PLATFORMS INC (META). Of the 22 guru strategies we follow META rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price rela
Today
Arvinas Announces Submission of New Drug Application to United States FDA for Vepdegestrant for Patients with ESR1-Mutated ER/HER2- Advanced or Metastatic Breast Cancer. – This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
Today
Meta Platforms chief legal officer sells $348249 in stock.
Thu Jun 5, 2025
Check Out What Whales Are Doing With META. Whales with a lot of money to spend have taken a noticeably bearish stance on Looking at options history for Meta Platforms (NASDAQ:) we detected 101 trades.If we consider the specifics of each trade it is accurate to state that 35% of the investors opened trades with ish expectations and 37% with bearish.From the overall spotted trades 16 are puts for a total amount of $829423 and 85 calls for a total amount of $9211257.Based on the trading activity it
Thu Jun 5, 2025
Eminems Music Publisher Sues Meta For $109 Million Over Alleged Song Theft. ) is facing a $109 million lawsuit fromPEOPLE. The lawsuit accuses Meta of copyright infringement and seeks damages of over $109 million.The lawsuit which does not name Eminem as a party claims that Meta'.s platforms—such as Original Audio and Reels Remix—allow users to use music owned by Eight Mile Style without proper licensing or credit. It also alleges that the songs have appeared in millions of videos and have b
Thu Jun 5, 2025
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma. HUTCHMED) (Nasdaq/AIM:HCM. HKEX:13) and Innovent Biologics Inc. (Innovent) (HKEX: 01801) today jointly announce that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine ki
Wed Jun 4, 2025
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma. HUTCHMED) (Nasdaq/AIM:HCM. HKEX:13) and Innovent Biologics Inc. (Innovent) (HKEX: 01801) today jointly announce that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine ki
Wed Jun 4, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
META Stock trends
META Stock performance
META Stock analysis
META investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
